

## CORRECTION



# Correction to: One year of experience with combined pharmacokinetic/pharmacogenetic monitoring of anti-TNF alpha agents: a retrospective study

Stefania Cheli , Diego Savino, Annalisa De Silvestri , Lorenzo Norsa, Naire Sansotta, Francesca Penagini, Dario Dilillo, Roberto Panceri, Dario Cattaneo, Emilio Clementi and Giovanna Zuin

© The Author(s), under exclusive licence to Springer Nature Limited 2023

*The Pharmacogenomics Journal* (2023) 23:140; <https://doi.org/10.1038/s41397-023-00311-0>

Correction to: *The Pharmacogenomics Journal* <https://doi.org/10.1038/s41397-023-00304-z>, published online 04 April 2023

In Table 3 of this article, some data were incorrect; the table should have appeared as shown below.

**Table 3.** Associations between the TNF $\alpha$  polymorphisms and clinical response.

Gene	Genotype	Steroid-free + PCDAI/PUCAI < 10		OR	95% CI	P value	CRP $\leq$ 0.5mg/dL + Calprotectin $\leq$ 150 $\mu$ g/g + PCDAI/PUCAI < 10		OR	95% CI	P value
		Yes n (%)	No n (%)				Yes n (%)	No n (%)			
<b>Infliximab</b>											
TNF $\alpha$ rs1800629 -308 G>A	GG GA + AA	38 (84.5) 2 (4.4)	3 (6.7) 2 (4.4)	12.6	1.28–124.5	<b>0.03</b>	20 (37) 1 (1.9)	26 (48.1) 7 (13)	5.38	0.61–47.4	0.13
TNF $\alpha$ rs361525 -238G>A	GG GA + AA	32 (71.1) 8 (17.8)	4 (8.9) 1 (2.2)	1.00	0.09–10.2	1.00	28 (51.8) 5 (9.3)	16 (29.6) 5 (9.3)	0.57	0.14–2.28	0.42
TNF $\alpha$ rs1799724 -857C>T	CC CT + TT	26 (57.8) 14 (31.1)	3 (6.7) 2 (4.4)	1.24	0.18–8.30	0.82	16 (29.6) 5 (9.3)	20 (37) 13 (24.1)	2.19	0.64–7.47	0.21
<b>Adalimumab</b>											
TNF $\alpha$ rs1800629 -308 G>A	GG GA + AA	10 (55.5) 3 (16.7)	4 (22.2) 1 (5.6)	0.83	0.06–10.59	0.88	5 (26.3) 2 (10.5)	10 (52.75) 2 (10.5)	0.5	0.05–4.67	0.54
TNF $\alpha$ rs361525 -238G>A	GG GA + AA	13 (72.2) 0 (0)	4 (22.2) 1 (5.6)	9.0	0.30–262	0.20	6 (31.6) 0 (0)	12 (63.1) 1 (5.3)	1.56	0.05–43.9	0.79
TNF $\alpha$ rs1799724 -857C>T	CC CT + TT	9 (50) 4 (22.2)	5 (27.8) 0 (0)	0.19	0.008–4.28	0.29	5 (26.3) 1 (5.3)	9 (47.4) 4 (21)	2.22	0.19–25.7	0.52

Bold values indicate statistical significance  $p < 0.05$ .

OR odds ratio, 95% CI confidence interval 95%, CRP C reactive protein.

The original article has been corrected.